The stock market is well past that period where almost anything China-related became an overnight sensation. That said, there are some powerful realities about the size of the Chinese economy and the opportunities in areas like healthcare. That brings us to the opportunity in Mindray Medical (MR). Mindray is one of the very few Chinese med-tech companies to have a legitimate business outside of China, as well as extensive growth opportunities within China. Margins, domestic competition, and an uncertain strategy in the U.S. are all valid reasons for concern, but Mindray just may be one of the better growth opportunities in med-tech right now.
Fourth Quarter's Results Come In Pretty Solid
While Mindray had previously guided the Street...
Only subscribers can access this article, which is part of the PRO research library covering 3,773 different stocks.
Growing numbers of fund managers and other investment professionals subscribe to Seeking Alpha PRO for equity research that is unavailable elsewhere, so they can: